CN110621320B - 青光眼的治疗 - Google Patents

青光眼的治疗 Download PDF

Info

Publication number
CN110621320B
CN110621320B CN201880031854.2A CN201880031854A CN110621320B CN 110621320 B CN110621320 B CN 110621320B CN 201880031854 A CN201880031854 A CN 201880031854A CN 110621320 B CN110621320 B CN 110621320B
Authority
CN
China
Prior art keywords
dextran sulfate
pharmaceutically acceptable
acceptable salt
glaucoma
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880031854.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN110621320A (zh
Inventor
L·布鲁斯
A·布鲁斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TX Medic AB
Original Assignee
TX Medic AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TX Medic AB filed Critical TX Medic AB
Priority claimed from PCT/SE2018/050506 external-priority patent/WO2018212708A1/en
Publication of CN110621320A publication Critical patent/CN110621320A/zh
Application granted granted Critical
Publication of CN110621320B publication Critical patent/CN110621320B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
CN201880031854.2A 2017-05-17 2018-05-16 青光眼的治疗 Active CN110621320B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE1750615 2017-05-17
SE1750615-5 2017-05-17
US201762555848P 2017-09-08 2017-09-08
US62/555,848 2017-09-08
PCT/SE2018/050506 WO2018212708A1 (en) 2017-05-17 2018-05-16 Treatment of glaucoma

Publications (2)

Publication Number Publication Date
CN110621320A CN110621320A (zh) 2019-12-27
CN110621320B true CN110621320B (zh) 2023-03-17

Family

ID=62245395

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880031854.2A Active CN110621320B (zh) 2017-05-17 2018-05-16 青光眼的治疗

Country Status (12)

Country Link
US (1) US11291684B2 (https=)
EP (1) EP3532072B1 (https=)
JP (1) JP6817466B2 (https=)
KR (1) KR102331421B1 (https=)
CN (1) CN110621320B (https=)
CA (1) CA3063851C (https=)
DK (1) DK3532072T3 (https=)
ES (1) ES2777836T3 (https=)
IL (1) IL270362B (https=)
PL (1) PL3532072T3 (https=)
PT (1) PT3532072T (https=)
RU (1) RU2759998C2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3074987A1 (en) * 2017-09-08 2019-03-14 Tx Medic Ab New use of dextran sulfate
GB202008919D0 (en) * 2020-06-11 2020-07-29 Univ Birmingham Polysaccharide conpositions and therapeutic gels
CN115531417B (zh) * 2022-11-14 2024-04-09 青岛海尔生物科技有限公司 ITGA6阳性iPSC源小梁网类细胞在制备治疗高眼压疾病药物中的应用及筛选方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02223525A (ja) * 1988-11-16 1990-09-05 Takeda Chem Ind Ltd 血管新生阻害剤
US5135920A (en) * 1988-11-16 1992-08-04 Takeda Chemical Industries, Ltd. Angiostatic agents
WO2015175565A2 (en) * 2014-05-12 2015-11-19 Purdue Research Foundation Selectin and icam/vcam peptide ligand conjugates
WO2016076780A1 (en) * 2014-11-11 2016-05-19 Tx Medic Ab New dextran sulfate

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4238482A (en) * 1978-09-29 1980-12-09 Peyman Gholam A Intraocular infusion irrigation solution and method
DE3705669A1 (de) 1987-02-21 1988-09-01 Thomae Gmbh Dr K Verwendung von dextransulfat zur herstellung eines arzneimittels zur behandlung und prophylaxe von gefaessverengungen und gefaessverschluessen
US5227372A (en) 1990-03-07 1993-07-13 Children's Medical Center Corporation Method for retaining ophthalmological agents in ocular tissues
CA2020199C (en) 1990-06-29 2002-08-20 Daniel Bar-Shalom Uses of sulphated sugars
US5605938A (en) 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
CA2331620A1 (en) 1998-05-11 1999-11-18 The Endowment For Research In Human Biology, Inc. Use of neomycin for treating angiogenesis-related diseases
GB9917092D0 (en) 1999-07-22 1999-09-22 Ml Lab Plc Treatment of angiogenesis-dependent conditions
WO2005110438A2 (en) 2004-04-15 2005-11-24 Massachusetts Institute Of Technology Methods and products related to the intracellular delivery of polysaccharides
SE0401182D0 (sv) 2004-05-05 2004-05-05 Q Med Ab Novel use of a viscoelastic composition
US20060154894A1 (en) 2004-09-15 2006-07-13 Massachusetts Institute Of Technology Biologically active surfaces and methods of their use
WO2007002139A2 (en) 2005-06-22 2007-01-04 The Trustees Of The University Of Pennsylvania Neuroprotection of retinal ganglion cells
US20140186339A1 (en) * 2006-10-27 2014-07-03 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions
US20130273096A1 (en) 2011-10-05 2013-10-17 Bruce A. Daniels Therapeutic Sulfated Polysaccharides, Compositions Thereof, and Methods for Treating Patients
WO2015190989A1 (en) 2014-06-12 2015-12-17 Tx Medic Ab The use of dextran sulfate having an average molecular weight below 10000 da for inducing angiogenisis in a subject
SE539575C2 (en) * 2015-07-30 2017-10-17 Tx Medic Ab Dextran sulfate for use in treating, inhibiting or preventing cardiac fibrosis
CN107137421A (zh) 2017-05-25 2017-09-08 青岛市中心医院 硫酸葡聚糖在制备抑制角膜血管新生药物中的应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02223525A (ja) * 1988-11-16 1990-09-05 Takeda Chem Ind Ltd 血管新生阻害剤
US5135920A (en) * 1988-11-16 1992-08-04 Takeda Chemical Industries, Ltd. Angiostatic agents
WO2015175565A2 (en) * 2014-05-12 2015-11-19 Purdue Research Foundation Selectin and icam/vcam peptide ligand conjugates
WO2016076780A1 (en) * 2014-11-11 2016-05-19 Tx Medic Ab New dextran sulfate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
EFFECT OF DEXTRAN SULFATE ON FIBRONECTIN-COLLAGEN INTERACTION;Erkki RUOSLAHTI等;《FEBS LETTERS》;19791130;第107卷(第1期);第51-54页 *

Also Published As

Publication number Publication date
PL3532072T3 (pl) 2020-09-21
ES2777836T3 (es) 2020-08-06
EP3532072B1 (en) 2020-01-01
EP3532072A1 (en) 2019-09-04
KR102331421B1 (ko) 2021-11-25
CA3063851C (en) 2023-09-19
IL270362B (en) 2021-04-29
BR112019024087A2 (pt) 2020-06-02
CN110621320A (zh) 2019-12-27
JP2020519742A (ja) 2020-07-02
RU2019136633A (ru) 2021-06-17
RU2759998C2 (ru) 2021-11-22
KR20200005560A (ko) 2020-01-15
US20210315920A1 (en) 2021-10-14
RU2019136633A3 (https=) 2021-06-17
PT3532072T (pt) 2020-03-05
US11291684B2 (en) 2022-04-05
CA3063851A1 (en) 2018-11-22
JP6817466B2 (ja) 2021-01-20
DK3532072T3 (da) 2020-04-06

Similar Documents

Publication Publication Date Title
Stepp et al. Reduced intraepithelial corneal nerve density and sensitivity accompany desiccating stress and aging in C57BL/6 mice
Yu et al. Neurokinin-1 receptor antagonism ameliorates dry eye disease by inhibiting antigen-presenting cell maturation and T helper 17 cell activation
Williams et al. Inhibition of the classical pathway of the complement cascade prevents early dendritic and synaptic degeneration in glaucoma
Carido et al. Characterization of a mouse model with complete RPE loss and its use for RPE cell transplantation
JP5643237B2 (ja) 光受容細胞のアポトーシスを抑制する方法
CN110621320B (zh) 青光眼的治疗
CN114173802A (zh) 用于治疗非渗出性黄斑变性和其他眼睛病症的肽
Yan et al. Smart coating by thermo-sensitive Pluronic F-127 for enhanced corneal healing via delivery of biological macromolecule progranulin
JP2011513290A (ja) ＶＥＧＦｘｘｘｂの新規な使用
Chiang et al. The ocular graft-versus-host disease: the path from current knowledge to future managements
WO2018212708A1 (en) Treatment of glaucoma
Trofimova Molecular mechanisms of retina pathology and ways of its correction
Fan et al. [Retracted] Effects of Recombinant Human Epidermal Growth Factor Eye Drops Combined with Phacoemulsification on Short‐and Long‐Term Visual Acuity Recovery and Related Dry Eye Complications in Patients with Senile Cataract
CN115737781A (zh) 枸杞糖肽新用途及药物
BR112019024087B1 (pt) Uso de sulfato de dextrano ou de um sal farmaceuticamente aceitável do mesmo para tratamento, inibição ou prevenção de glaucoma
Pastor Jimeno et al. Proliferative vitreoretinopathy: A new concept of disease pathogenesis and practical consequences
Biagioni Fighting inflammation to save cones: anti-inflammatory approaches to slow down cone degeneration in a mouse model of retinitis pigmentosa
WO2024172043A1 (ja) 網膜色素上皮裂孔の治療薬
Wu Neuroregenerative and anti-inflammatory effects of decorin on the injured cornea
Reina-Torres et al. 10. VEGF expression is elevated in high-flow regions of mouse trabecular meshwork.
Xiao-Chen et al. A New Experimental Model of Krypton Laser-Induced Choroidal Neovascularization in Tree Shrew
US20090291887A1 (en) Proteins of the SDF-1-Family for the Manufacturing of a Medicament
Adlju et al. Comparing the mid-term efficacy and safety of the Stegmann Canal Expander Canaloplasty with the prolene suture Canaloplasty in cases of open angle glaucoma
WO2021163304A1 (en) Activation of neuropeptide receptors on plasmacytoid dendritic cells to treat or prevent ocular diseases associated with neovascularization and inflammation
Echevarria The Role of Interleukin-6 in Health and Disease of Retinal Ganglion Cells

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant